Form 4: ARS Pharmaceuticals CEO Sells Shares Under Pre-Arranged Trading Plan

ARS Pharmaceuticals CEO Richard E. Lowenthal sold 150,000 shares of common stock through trusts under a pre-arranged trading plan.

Summary

• Richard E. Lowenthal, the President and CEO of ARS Pharmaceuticals, Inc., sold a total of 150,000 shares of common stock on December 10, 2024.
• The sales were executed through three different trusts: the Richard E. Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Sarina Tanimoto Charitable Remainder UniTrust.
• The sales were conducted under a Rule 10b5-1 trading plan established on March 31, 2023.
• 50,000 shares were sold by the Richard E. Lowenthal Charitable Remainder UniTrust at a weighted average price of $13.1653, with prices ranging from $12.94 to $13.535.
• 50,000 shares were sold by the Lowenthal-Tanimoto Family Trust at a weighted average price of $13.1631, with prices ranging from $12.94 to $13.535.
• The remaining 50,000 shares were sold by the Sarina Tanimoto Charitable Remainder UniTrust.
• The CEO disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by the CEO under a pre-arranged plan, which is neither positive nor negative for the company's prospects.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

Sales by executives under 10b5-1 plans are common and are generally not seen as a negative signal, as they are pre-arranged and often for personal financial planning.

Comparison to Industry Standards

• Executive stock sales are a common practice across the pharmaceutical industry, with many executives using 10b5-1 plans to manage their personal finances.
• The reported price range of $12.94 to $13.535 is within the typical trading range for a company of ARS Pharmaceuticals' size and market capitalization.
• Comparable companies in the biotech sector often see similar patterns of executive stock sales.

Stakeholder Impact

• The stock sale may have a minor impact on the stock price in the short term, but it is unlikely to have a significant long-term effect on shareholders.
• The sale does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

ARS Pharmaceuticals, Richard E. Lowenthal, stock sale, Rule 10b5-1, insider trading, trust, common stock